Centene (NYSE:CNC) Given New $50.00 Price Target at Mizuho

Key Points

• Mizuho raised its price target on Centene to $50 (from $41) while keeping a "neutral" rating — the firm’s target implies about a 5.7% downside, and the Street consensus target is roughly $51.41 with an average rating of "Hold" (6 Buy / 11 Hold / 2 Sell).
• Centene posted a strong Q1 beat (GAAP EPS $3.37 vs. $2.12 est., revenue $49.94B vs. $47.58B), which spurred multiple analyst upgrades and price-target increases across the brokerage community.
• Key headwinds include legislative risk from H.R. 8375 that could raise utilization and compliance costs, plus ongoing pressure from declines in commercial/individual enrollment that may limit revenue upside.

Centene (NYSE:CNC - Get Free Report) had its target price lifted by analysts at Mizuho from $41.00 to $50.00 in a research report issued on Wednesday,MarketScreener reports. The brokerage presently has a "neutral" rating on the stock. Mizuho's target price would suggest a potential downside of 5.69% from the stock's current price.

Several other equities analysts have also issued reports on the company. Cantor Fitzgerald raised Centene from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $41.00 to $60.00 in a report on Tuesday. Oppenheimer reissued an "outperform" rating and issued a $58.00 target price (up from $45.00) on shares of Centene in a research report on Wednesday. Jefferies Financial Group raised their price target on Centene from $39.00 to $48.00 and gave the stock a "hold" rating in a research note on Wednesday. TD Cowen boosted their price objective on Centene from $34.00 to $38.00 and gave the company a "hold" rating in a research note on Wednesday, February 11th. Finally, JPMorgan Chase & Co. decreased their price objective on Centene from $45.00 to $41.00 and set a "neutral" rating for the company in a report on Thursday, March 19th. Six analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Centene presently has an average rating of "Hold" and a consensus price target of $51.41.

Centene Stock Performance

Shares of CNC opened at $53.02 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.87. Centene has a 52-week low of $25.08 and a 52-week high of $64.15. The stock has a 50 day moving average price of $38.71 and a 200 day moving average price of $39.35. The company has a market capitalization of $26.07 billion, a price-to-earnings ratio of -3.89, a price-to-earnings-growth ratio of 0.96 and a beta of 0.59.

Centene (NYSE:CNC - Get Free Report) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $3.37 earnings per share for the quarter, topping the consensus estimate of $2.12 by $1.25. The business had revenue of $49.94 billion during the quarter, compared to the consensus estimate of $47.58 billion. Centene had a negative net margin of 3.43% and a positive return on equity of 4.25%. The company's revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.90 EPS. Research analysts predict that Centene will post 3.01 EPS for the current fiscal year.

Institutional Trading of Centene

A number of hedge funds have recently added to or reduced their stakes in CNC. DV Equities LLC acquired a new position in shares of Centene in the fourth quarter valued at approximately $26,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of Centene during the fourth quarter worth $28,000. Addison Advisors LLC grew its position in Centene by 455.6% in the 3rd quarter. Addison Advisors LLC now owns 739 shares of the company's stock valued at $26,000 after buying an additional 606 shares during the last quarter. SBI Securities Co. Ltd. increased its stake in Centene by 118.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 749 shares of the company's stock valued at $31,000 after buying an additional 406 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in shares of Centene in the 3rd quarter worth $27,000. 93.63% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Centene

Here are the key news stories impacting Centene this week:

• Positive Sentiment: Q1 earnings & guidance beat — Centene reported a sizable EPS beat and raised its 2026 outlook, citing declining medical costs, steady premium growth and effective cost controls; that drove the initial rally. Centene Analysts Increase Their Forecasts Following Upbeat Q1 Earnings
• Positive Sentiment: Analyst upgrades and price-target lifts — Multiple brokerages moved targets higher (Truist, UBS, Bank of America raised ratings/targets), supporting momentum and investor confidence. Truist raises Centene price target to $58 UBS adjusts price target on Centene to $55
• Positive Sentiment: Unusual options activity — Heavy call buying was recorded around the report, indicating speculative and institutional bullish interest that can amplify intraday moves.
• Neutral Sentiment: Technicals/support — Chart analysis notes the stock found long-term support from prior lows, which may attract technical buyers but also invites profit-taking debate on rally extent. Stock Of The Day: Where Will The Centene Rally End?
• Neutral Sentiment: Earnings-call tone cautious — Management highlighted progress on cost controls and Medicaid, but was measured on membership trends and longer-term margin drivers; investors should watch upcoming quarters for sustainability. Centene Earnings Call: Big EPS Beat, Cautious Outlook
• Negative Sentiment: Legislative risk — New bill H.R. 8375 (Medicare Advantage Improvement Act of 2026) would tighten oversight, require less restrictive medical-necessity criteria and faster authorizations for Medicare Advantage plans, which could raise utilization and compliance costs for Centene. New Bill: H.R. 8375: Medicare Advantage Improvement Act of 2026
• Negative Sentiment: Membership mix pressure — несмотря strong Medicaid performance, Centene still faces declines in commercial/individual enrollment, which could limit revenue upside if persistent. Centene Stock Jumps With Medicaid Strength, But Commercial Enrollment Slide Persists

Centene Company Profile

Centene Corporation NYSE: CNC is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children's Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.

Centene's offerings extend beyond traditional insurance to include a range of specialty and support services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.